Connect with us


Exosome diagnostics and therapeutics market to reach USD 6,848M by 2032

The exosome diagnostics and therapeutics market is projected to grow from USD 59 million in 2024 to USD 6,848 million by 2032 at a CAGR of 108.9%. The market is being primarily driven by the emerging potential of exosome-based liquid biopsy, which offers non-invasive options for disease diagnosis, prognosis, and treatment response monitoring across various health conditions. Additionally, significant technological advancements have led to the evolution of biopsy techniques, with liquid biopsies offering several advantages over traditional methods, such as non-invasiveness, reduced procedural costs, and easy disease monitoring.

Furthermore, exosomes, known for their stability and ability to carry genetic material such as cellular DNA, mRNA, and miRNA, have gained traction in clinical research as a novel source of biomarkers suitable for diagnostic applications. The market is segmented into exosome diagnostics and exosome therapeutics, with the former accounting for the largest share in 2023. Key contributors to market revenue include products like the ExoDx prostate cancer test, with few others in the pipeline. Additionally, the kits & reagents segment is expected to dominate the exosome diagnostics market, attributed to the growing demand for noninvasive commercial diagnostic kits.

Exosome diagnostics segment leads market share in 2023
In 2023, the exosome diagnostics segment emerged as the frontrunner in market share, underscoring its pivotal role in driving the growth trajectory of the exosome diagnostics and therapeutics market.

Market segmentation highlights
The market is segmented into exosome diagnostics and exosome therapeutics. Notably, the ExoDx prostate cancer test by Exosome Diagnostics, a subsidiary of Bio-Techne, stands out as a key revenue contributor throughout the forecast period.

Dominance of kits & reagents segment
The kits & reagents segment is poised to dominate the exosome diagnostics market, fueled by escalating demand for noninvasive diagnostic kits. Despite Bio-Techne’s dominance in this segment until 2029, the instruments & services segment is expected to witness significant traction in the near future.

Exponential growth in blood & blood plasma segment
The blood & blood plasma segment is anticipated to experience exponential growth from 2024 to 2029. Exosomes derived from blood plasma play crucial roles in intercellular communication and tissue homeostasis, driving their increased adoption in liquid biopsy procedures.

Cancer emerges as dominant application segment
In the realm of exosome therapeutics, cancer is poised to emerge as the dominant application segment. Exosomes serve as effective carriers for therapeutic cargo, facilitating targeted drug delivery and early diagnosis of cancer through detection of tumor-specific molecules.

North America’s market dominance
Throughout the forecast period, North America, particularly the United States and Canada, is set to dominate the global exosome diagnostics and therapeutics market. The region’s strong regulatory framework, coupled with significant investments in R&D, underscores its leading position in driving market growth. MarketsandMarkets™

Copyright © 2024 Medical Buyer

error: Content is protected !!